The past year has seen a number of developments in HIV drug development and research that made headlines across the media, most notably with Gilead’s publication of glowing clinical data from two Phase III trials of its twice-a-year pre-exposure prophylactic lenacapavir. Only 12 years since the initial approval of Gilead’s daily oral PrEP pill Truvada (emtricitabine/tenofovir disoproxil fumarate), the potential approval of lenacapavir’s use as PrEP could dramatically improve the lives of those at risk of contracting HIV.
Medicines Patent Pool Doubles Down On Increased Access To HIV Treatments
MPP’s Charles Gore Discusses The Organization’s Efforts In HIV Treatment In 2024
Rounding up another important year in the fight against HIV, the MPP’s executive director Charles Gore speaks to Generics Bulletin about the organization’s biggest milestones in the past 12 months.
